Moleculin BiotechMBRX
Market Cap: $7M
About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Employees: 18
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
1.91% more ownership
Funds ownership: 11.61% [Q1] → 13.52% (+1.91%) [Q2]
21% less funds holding
Funds holding: 19 [Q1] → 15 (-4) [Q2]
28% less capital invested
Capital invested by funds: $1.53M [Q1] → $1.1M (-$432K) [Q2]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for MBRX.
Financial journalist opinion
Based on 4 articles about MBRX published over the past 30 days